The Application of CRISPR/Cas Systems for Antiviral Therapy.
CRISPR
Cas13
Cas9
HIV
RNA virus
SARS-CoV-2
antiviral
hepatitis B
Journal
Frontiers in genome editing
ISSN: 2673-3439
Titre abrégé: Front Genome Ed
Pays: Switzerland
ID NLM: 101775540
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
07
2021
accepted:
23
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
2
11
2021
Statut:
epublish
Résumé
As CRISPR/Cas systems have been refined over time, there has been an effort to apply them to real world problems, such as developing sequence-targeted antiviral therapies. Viruses pose a major threat to humans and new tools are urgently needed to combat these rapidly mutating pathogens. Importantly, a variety of CRISPR systems have the potential to directly cleave DNA and RNA viral genomes, in a targeted and easily-adaptable manner, thus preventing or treating infections. This perspective article highlights recent studies using different Cas effectors against various RNA viruses causing acute infections in humans; a latent virus (HIV-1); a chronic virus (hepatitis B); and viruses infecting livestock and animal species of industrial importance. The outlook and remaining challenges are discussed, particularly in the context of tacking newly emerging viruses, such as SARS-CoV-2.
Identifiants
pubmed: 34723245
doi: 10.3389/fgeed.2021.745559
pii: 745559
pmc: PMC8549726
doi:
Types de publication
Journal Article
Langues
eng
Pagination
745559Informations de copyright
Copyright © 2021 Baddeley and Isalan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Ther Nucleic Acids. 2020 Jun 5;20:480-490
pubmed: 32278307
Commun Biol. 2020 Jul 31;3(1):413
pubmed: 32737398
J Virol. 2017 Mar 29;91(8):
pubmed: 28122981
Front Microbiol. 2018 Feb 16;9:209
pubmed: 29503634
PLoS Pathog. 2017 Feb 23;13(2):e1006206
pubmed: 28231264
Nat Commun. 2019 Jul 2;10(1):2753
pubmed: 31266936
BMJ Glob Health. 2021 Apr;6(4):
pubmed: 33893144
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
J Control Release. 2021 Feb 10;330:61-71
pubmed: 33333121
Sci Rep. 2013;3:2510
pubmed: 23974631
Nature. 2021 May;593(7859):429-434
pubmed: 34012082
Sci Rep. 2020 Jun 15;10(1):9617
pubmed: 32541822
Front Bioeng Biotechnol. 2020 Jul 15;8:841
pubmed: 32760714
Mol Biol (Mosk). 2019 Mar-Apr;53(2):311-323
pubmed: 31099781
Virology. 2015 May;479-480:213-20
pubmed: 25759096
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1400-1405
pubmed: 33092788
Sci Rep. 2016 Mar 04;6:22555
pubmed: 26939770
Mol Ther Nucleic Acids. 2018 Sep 7;12:242-253
pubmed: 30195763
Theranostics. 2021 Jan 1;11(2):649-664
pubmed: 33391497
Antiviral Res. 2018 Mar;151:63-70
pubmed: 29337166
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11461-6
pubmed: 25049410
Antiviral Res. 2018 Apr;152:58-67
pubmed: 29458131
Front Microbiol. 2018 Sep 11;9:2151
pubmed: 30254624
Science. 2018 Apr 27;360(6387):439-444
pubmed: 29449508
Curr Opin Microbiol. 2017 Jun;37:67-78
pubmed: 28605718
Methods Protoc. 2021 Jun 08;4(2):
pubmed: 34201194
Int J Biol Sci. 2019 Jan 1;15(2):481-492
pubmed: 30745836
Mol Ther Nucleic Acids. 2018 Sep 7;12:275-282
pubmed: 30195766
Nat Med. 2016 Aug;22(8):839-50
pubmed: 27400264
Gene Ther. 2016 Aug;23(8-9):690-5
pubmed: 27194423
Cell. 2020 May 14;181(4):865-876.e12
pubmed: 32353252
Mol Cell. 2018 Apr 19;70(2):327-339.e5
pubmed: 29551514
Front Microbiol. 2021 Jun 26;12:665184
pubmed: 34254007
Innovation (N Y). 2020 Aug 05;1(2):100034
pubmed: 34557710
Cell Mol Life Sci. 2019 May;76(9):1779-1794
pubmed: 30673820
Int J Biol Sci. 2019 Jul 25;15(9):1993-2005
pubmed: 31523199
Appl Microbiol Biotechnol. 2018 Nov;102(21):9255-9265
pubmed: 30151606
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Science. 2010 Jan 8;327(5962):167-70
pubmed: 20056882
Nat Commun. 2020 Nov 27;11(1):6065
pubmed: 33247091
Biomed Pharmacother. 2021 Apr;136:111239
pubmed: 33454599
Cell. 2021 Jan 21;184(2):323-333.e9
pubmed: 33306959
Virol Sin. 2019 Aug;34(4):444-453
pubmed: 31218589
Nat Med. 2005 Sep;11(9):944-51
pubmed: 16116432
Insect Mol Biol. 2019 Feb;28(1):112-122
pubmed: 30120848
Nature. 2021 Sep;597(7878):720-725
pubmed: 34489594
Transbound Emerg Dis. 2020 Mar;67(2):564-571
pubmed: 31541593
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Virol. 2018 Jul 31;92(16):
pubmed: 29925651
Viruses. 2018 Jan 16;10(1):
pubmed: 29337866
Nat Rev Genet. 2018 Dec;19(12):770-788
pubmed: 30323312
J Pharm Sci. 2020 Jan;109(1):62-67
pubmed: 31589876
Mol Cell. 2019 Dec 5;76(5):826-837.e11
pubmed: 31607545
Front Immunol. 2019 Aug 08;10:1846
pubmed: 31440241
Nucleic Acids Res. 2020 Jun 4;48(10):5527-5539
pubmed: 32282899
J Am Chem Soc. 2018 May 30;140(21):6596-6603
pubmed: 29668265
Mol Ther Nucleic Acids. 2020 Mar 6;19:1460-1469
pubmed: 32160714
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Mol Ther Methods Clin Dev. 2021 Jun 11;21:729-740
pubmed: 33969146
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
Mol Ther Nucleic Acids. 2020 Sep 4;21:147-155
pubmed: 32585623
Mol Ther Methods Clin Dev. 2020 Nov 26;20:258-275
pubmed: 33473359
Cell. 2018 Apr 19;173(3):665-676.e14
pubmed: 29551272
Nat Biotechnol. 2021 Jun;39(6):717-726
pubmed: 33536629
Nat Med. 2019 Feb;25(2):249-254
pubmed: 30692695
Science. 2018 Apr 27;360(6387):444-448
pubmed: 29700266
Front Immunol. 2018 Sep 11;9:2080
pubmed: 30254645
Nat Methods. 2021 May;18(5):499-506
pubmed: 33941935